Status & Updates
March 6, 2018: TINA.org, AARP, AARP Foundation, National Consumers League, and a group of advertising law academics file a Motion for Leave to file an amici curiae brief in support of reversing the District Court’s decision. To read more about TINA.org’s involvement in the Second Circuit appeal, click here.
February 28, 2018: The FTC and New York AG file their appellate briefs arguing that their case was improperly dismissed by the District Court.
November 15, 2017: The FTC and New York AG file Notices of Appeal indicating that they will be appealing the dismissal decision to the Second Circuit Court of Appeals.
October 2017: The BBB changes its rating of Quincy Bioscience back to an A+.
September 28, 2017: The FTC and New York Attorney General’s lawsuit filed against Quincy Bioscience was dismissed because the Court determined that they failed to show that the company lacks proper substantiation for its claims about Prevagen’s ability to improve memory.
January 10, 2017: The BBB changes its A+ rating of Quincy Bioscience to “No Rating.”
January 9, 2017: The FTC, together with the New York Attorney General, file a lawsuit against Quincy Bioscience for its deceptive advertising of Prevagen as able to improve memory.
After the filing of the lawsuit, TINA.org sends letters to the same five major TV networks it had notified in January 2016 (ABC, NBC, FOX, The Weather Channel, and Turner Broadcasting System) to notify them of the federal lawsuit filed against Quincy Bioscience and urging them to cease airing ads for Prevagen. TINA.org also sends a letter to the BBB notifying it of the lawsuit and urging it once again to re-evaluate its A+ rating of the company.
January 19, 2016: TINA.org sends letters to five major TV networks (ABC, NBC, FOX, The Weather Channel, and Turner Broadcasting System) that air Prevagen commercials putting them on notice that the commercials are deceptive and in violation of the networks’ own stated policies to only air truthful marketing.
TINA.org also sends a letter to the BBB calling on the organization to re-evaluate its A+ rating of Quincy Bioscience.
September 17, 2015: After getting no response from Quincy Bioscience, TINA.org sends a complaint letter to the FTC urging the agency to take action to halt the company’s deceptive marketing of Prevagen.
September 8, 2015: TINA.org sends a warning letter to Quincy Bioscience regarding its deceptive marketing campaign for Prevagen, and asking that the company correct the issues within one week.